Axa’s BioCryst Pharmaceuticals BCRX Stock Holding History

Axa’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-53,400	Closed	-$153K	–	1174
2019 Q3	$153K	Buy	+53,400	New	+$166K	﹤0.01%	1260
2016 Q1	–	Sell	-634,873	Closed	-$6.55M	–	1329
2015 Q4	$6.55M	Sell	634,873 -13,345	-2%	-$133K	0.03%	488
2015 Q3	$7.39M	Buy	648,218 +297,890	+85%	+$3.98M	0.03%	457
2015 Q2	$5.23M	Hold	350,328	–	–	0.02%	582
2015 Q1	$3.16M	Buy	350,328 +24,741	+8%	+$256K	0.01%	700
2014 Q4	$3.96M	Buy	+325,587	New	+$3.6M	0.02%	621

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Axa's BCRX Position: Q4 2019 in Review

Axa sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2019, closing a stake of 53,400 shares — an estimated $153K sold.

Axa first reported a position in BCRX in Q4 2014 and held it in 6 quarters. The position peaked at $7.39M in Q3 2015. 136 funds tracked by Wall St. Rank hold BCRX as of Q4 2019.

Axa reported no remaining BioCryst Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Axa sold 53,400 BioCryst Pharmaceuticals shares in Q4 2019, an estimated $153K.
Axa first reported a position in BioCryst Pharmaceuticals in Q4 2014 and held it in 6 quarters.
Axa's BioCryst Pharmaceuticals position peaked at $7.39M in Q3 2015.
136 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2019.

Based on Axa's 13F filing for Q4 2019, filed 18 Feb 2020.